Eliem Therapeutics Inc (ELYM)
8.02
-0.17
(-2.08%)
USD |
NASDAQ |
May 15, 14:24
Eliem Therapeutics Research and Development Expense (Quarterly): 3.127M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.127M |
| September 30, 2023 | 2.876M |
| June 30, 2023 | 3.688M |
| March 31, 2023 | 5.72M |
| December 31, 2022 | 4.927M |
| September 30, 2022 | 4.258M |
| June 30, 2022 | 8.769M |
| March 31, 2022 | 8.26M |
| Date | Value |
|---|---|
| December 31, 2021 | 6.879M |
| September 30, 2021 | 5.989M |
| June 30, 2021 | 5.793M |
| March 31, 2021 | 4.661M |
| December 31, 2020 | 4.412M |
| September 30, 2020 | 1.947M |
| June 30, 2020 | 1.36M |
| March 31, 2020 | 1.623M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.36M
Minimum
Jun 2020
8.769M
Maximum
Jun 2022
4.643M
Average
4.536M
Median
Research and Development Expense (Quarterly) Benchmarks
| Alpine Immune Sciences Inc | 22.46M |
| Candel Therapeutics Inc | 7.258M |
| Cyclacel Pharmaceuticals Inc | 3.518M |
| Lipocine Inc | 2.819M |
| GlycoMimetics Inc | 6.026M |